Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,765 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.
Rerks-Ngarm S, Paris RM, Chunsutthiwat S, Premsri N, Namwat C, Bowonwatanuwong C, Li SS, Kaewkungkal J, Trichavaroj R, Churikanont N, de Souza MS, Andrews C, Francis D, Adams E, Flores J, Gurunathan S, Tartaglia J, O'Connell RJ, Eamsila C, Nitayaphan S, Ngauy V, Thongcharoen P, Kunasol P, Michael NL, Robb ML, Gilbert PB, Kim JH. Rerks-Ngarm S, et al. Among authors: flores j. J Infect Dis. 2013 Apr 15;207(8):1195-205. doi: 10.1093/infdis/jis478. Epub 2012 Jul 26. J Infect Dis. 2013. PMID: 22837492 Clinical Trial.
Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study.
Cao H, Kaleebu P, Hom D, Flores J, Agrawal D, Jones N, Serwanga J, Okello M, Walker C, Sheppard H, El-Habib R, Klein M, Mbidde E, Mugyenyi P, Walker B, Ellner J, Mugerwa R; HIV Network for Prevention Trials. Cao H, et al. Among authors: flores j. J Infect Dis. 2003 Mar 15;187(6):887-95. doi: 10.1086/368020. Epub 2003 Mar 6. J Infect Dis. 2003. PMID: 12660934 Clinical Trial.
Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load.
Celum CL, Buchbinder SP, Donnell D, Douglas JM Jr, Mayer K, Koblin B, Marmor M, Bozeman S, Grant RM, Flores J, Sheppard HW. Celum CL, et al. Among authors: flores j. J Infect Dis. 2001 Jan 1;183(1):23-35. doi: 10.1086/317658. Epub 2000 Dec 8. J Infect Dis. 2001. PMID: 11106536
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.
Belshe RB, Stevens C, Gorse GJ, Buchbinder S, Weinhold K, Sheppard H, Stablein D, Self S, McNamara J, Frey S, Flores J, Excler JL, Klein M, Habib RE, Duliege AM, Harro C, Corey L, Keefer M, Mulligan M, Wright P, Celum C, Judson F, Mayer K, McKirnan D, Marmor M, Woody G; National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group and HIV Network for Prevention Trials (HIVNET). Belshe RB, et al. Among authors: flores j. J Infect Dis. 2001 May 1;183(9):1343-52. doi: 10.1086/319863. Epub 2001 Apr 10. J Infect Dis. 2001. PMID: 11294665 Clinical Trial.
Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
Wright PF, Mestecky J, McElrath MJ, Keefer MC, Gorse GJ, Goepfert PA, Moldoveanu Z, Schwartz D, Spearman PW, El Habib R, Spring MD, Zhu Y, Smith C, Flores J, Weinhold KJ; National Institutes of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Wright PF, et al. Among authors: flores j. J Infect Dis. 2004 Apr 1;189(7):1221-31. doi: 10.1086/382088. Epub 2004 Mar 15. J Infect Dis. 2004. PMID: 15031791 Clinical Trial.
AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines.
Kent SJ, Cooper DA, Chhi Vun M, Shao Y, Zhang L, Ganguly N, Bela B, Tamashiro H, Ditangco R, Rerks-Ngarm S, Pitisuttithum P, Van Kinh N, Bernstein A, Osmanov S; AIDS Vaccine for Asia Network investigators and supporters. Kent SJ, et al. PLoS Med. 2010 Sep 21;7(9):e1000331. doi: 10.1371/journal.pmed.1000331. PLoS Med. 2010. PMID: 20877474 Free PMC article.
Seeking new pathways for HIV vaccine discovery.
Flores J. Flores J. Future Microbiol. 2009 Feb;4(1):1-7. doi: 10.2217/17460913.4.1.1. Future Microbiol. 2009. PMID: 19207094 Free article. Review. No abstract available.
Progress in HIV vaccine development.
Johnston MI, Flores J. Johnston MI, et al. Among authors: flores j. Curr Opin Pharmacol. 2001 Oct;1(5):504-10. doi: 10.1016/s1471-4892(01)00086-8. Curr Opin Pharmacol. 2001. PMID: 11764777 Review.
Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa.
Gray CM, Williamson C, Bredell H, Puren A, Xia X, Filter R, Zijenah L, Cao H, Morris L, Vardas E, Colvin M, Gray G, McIntyre J, Musonda R, Allen S, Katzenstein D, Mbizo M, Kumwenda N, Taha T, Karim SA, Flores J, Sheppard HW. Gray CM, et al. Among authors: flores j. AIDS Res Hum Retroviruses. 2005 Apr;21(4):285-91. doi: 10.1089/aid.2005.21.285. AIDS Res Hum Retroviruses. 2005. PMID: 15943570
The use of nonhuman primate models in HIV vaccine development.
Morgan C, Marthas M, Miller C, Duerr A, Cheng-Mayer C, Desrosiers R, Flores J, Haigwood N, Hu SL, Johnson RP, Lifson J, Montefiori D, Moore J, Robert-Guroff M, Robinson H, Self S, Corey L. Morgan C, et al. Among authors: flores j. PLoS Med. 2008 Aug 12;5(8):e173. doi: 10.1371/journal.pmed.0050173. PLoS Med. 2008. PMID: 18700814 Free PMC article.
1,765 results